Management of Pulmonary Embolism
The management of pulmonary embolism is fundamentally driven by risk stratification based on hemodynamic stability, with immediate anticoagulation for all patients and systemic thrombolysis reserved exclusively for high-risk (hemodynamically unstable) PE. 1
Risk Stratification Framework
The cornerstone of PE management is immediate risk stratification to identify patients at high risk of early mortality. This stratification determines the entire treatment pathway 1:
- High-risk PE: Presence of hemodynamic instability (shock or persistent hypotension)
- Intermediate-risk PE: Hemodynamically stable but with evidence of right ventricular dysfunction and/or elevated cardiac biomarkers
- Low-risk PE: Hemodynamically stable without RV dysfunction or biomarker elevation
Acute Phase Anticoagulation
Initiation of Treatment
Start anticoagulation immediately without delay in patients with high or intermediate clinical probability of PE while diagnostic workup is in progress 1. This is a Class I recommendation that prioritizes early treatment to prevent mortality.
Parenteral Anticoagulation
For patients requiring parenteral therapy 1:
- Prefer LMWH or fondaparinux over unfractionated heparin in hemodynamically stable patients (Class I)
- Use weight-adjusted bolus UFH in suspected high-risk PE with hemodynamic instability 1
Oral Anticoagulation Selection
When initiating oral anticoagulation, prefer a NOAC (apixaban, dabigatran, edoxaban, or rivaroxaban) over vitamin K antagonists 1. This is a Class I, Level A recommendation based on superior safety and efficacy profiles.
Critical Contraindications to NOACs:
- Severe renal impairment
- Pregnancy and lactation
- Antiphospholipid antibody syndrome 1
For these patients, use VKA with overlapping parenteral anticoagulation until INR reaches 2.5 (range 2.0-3.0) 1.
Reperfusion Therapy
High-Risk PE
Administer systemic thrombolytic therapy to all patients with high-risk PE (Class I recommendation) 1. This directly addresses mortality reduction in hemodynamically unstable patients.
Perform surgical pulmonary embolectomy when thrombolysis is contraindicated or has failed 1. This is the definitive mechanical intervention for patients who cannot receive or do not respond to thrombolysis.
Intermediate and Low-Risk PE
Do NOT routinely administer systemic thrombolysis as primary treatment in intermediate- or low-risk PE (Class III, Level B) 1. The bleeding risk outweighs potential benefits in these hemodynamically stable patients.
Administer rescue thrombolytic therapy only if hemodynamic deterioration occurs on anticoagulation treatment 1. This represents a critical transition point where the patient's risk category has changed.
Duration of Anticoagulation
All patients with PE require therapeutic anticoagulation for at least 3 months 1. Beyond this minimum:
- Discontinue after 3 months if first PE secondary to major transient/reversible risk factor (surgery, trauma, immobilization) 1
- Continue indefinitely for recurrent VTE not related to transient risk factors 1
- Continue VKA indefinitely (not NOACs) for antiphospholipid antibody syndrome 1
Reassess drug tolerance, adherence, hepatic/renal function, and bleeding risk at regular intervals in patients on extended anticoagulation 1.
Special Considerations
Inferior Vena Cava Filters
Do NOT routinely use IVC filters (Class III, Level A) 1. Consider only for:
- Absolute contraindications to anticoagulation (Class IIa)
- PE recurrence despite therapeutic anticoagulation (Class IIa) 1
Pregnancy
- Use therapeutic fixed-dose LMWH based on early pregnancy weight 1
- Never use NOACs during pregnancy or lactation 1
- Avoid spinal/epidural procedures within 24 hours of last LMWH dose 1
Early Discharge
Consider early discharge and home treatment for carefully selected low-risk PE patients if proper outpatient care and anticoagulation can be provided (Class IIa, Level A) 1. This improves quality of life without compromising safety.
Post-PE Follow-Up
Routinely re-evaluate all patients 3-6 months after acute PE 1. This identifies potential chronic thromboembolic pulmonary hypertension (CTEPH).
Refer symptomatic patients with persistent perfusion defects beyond 3 months to a pulmonary hypertension/CTEPH expert center 1. Early identification and referral of CTEPH significantly impacts long-term morbidity and mortality.
Critical Pitfalls to Avoid
- Never delay anticoagulation while awaiting diagnostic confirmation in high/intermediate probability patients
- Never measure D-dimers in high clinical probability patients—normal results do not exclude PE 1
- Never use NOACs in severe renal impairment, pregnancy, or antiphospholipid syndrome
- Never give systemic thrombolysis to hemodynamically stable patients as routine treatment
- Never use routine IVC filters—they increase DVT risk without mortality benefit